The ICMR analysis found that the BPaL regimen is "both more effective and cost-saving" compared to the current standard of ...

In a federally funded clinical trial led by Johns Hopkins Medicine, people with tuberculosis infections (but not HIV) in two ...

Tuberculosis remains one of the top infectious disease killers worldwide, a challenge amplified by drug-resistant forms of the disease. Now, in a major step forward, an international clinical trial ...

Researchers at the Jacobs School of Medicine and Biomedical Sciences have developed a new inhalable form of tuberculosis (TB) treatment that could significantly reduce the burden of current therapy.

Tuberculosis (TB) is a serious infectious disease caused by the bacterium Mycobacterium tuberculosis. While multidrug treatment regimens are the standard of care, the lengthy treatment schedule and ...

Researchers at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo have developed a new ...

An ICMR study has found that the six-month all-oral treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis are cost-effective and offer improved health outcomes compared to ...

A medication developed in the 1950s to treat Parkinson's disease may offer a powerful new tool in the fight against tuberculosis (TB), according to new research from the University of British Columbia ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, investigators ...

Health workers in developing countries know that isolating tuberculosis patients is an outdated and potentially harmful ...